Search results: Sage Journals

Restricted accessOtherFirst published January, 2005

Adverse Event Analysis and MedDRA: Business as Usual or Challenge? *

Jürgen Kübler, Richardus Vonk, Stefan Beimel [...]

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 2000

Establishing a Meddra Safety Surveillance Unit

Thanh T. van Doan

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2002

Converting Legacy Data to Meddra: Approach and Implications *

Thanh Van T. Doan

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2006

Proposed Terminology Changes to Facilitate the Analysis of MedDRA®-Coded Data

Anna C. Zhao-Wong, Eva Rump, Tomás Moraleda [...]

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1998

A Preliminary Assessment of the Impact of MEDDRA on Adverse Event Reports and Product Labeling

Claudia A. White

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2001

Using Meddra for Adverse Events in Cancer Trials: Experience,Caveats,and Advice

Lothar T. Tremmel

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published October, 2001

Defining Treatment-Emergent Adverse Events with the Medical Dictionary for Regulatory Activities (MedDRA) *

Mary E. Nilsson, Stephanie C. Koke

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published October, 2002

Data Normalization Techniques and Autocoding Algorithms for the Medical Dictionary for Regulatory Activities (MedDRA)

Mike Don Tucker

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published August, 2001

Medicinal Dictionary (MedDRA): Indications and reactions. Applications in pharmacovigilance

Arthur P. Meiners

Pharmaceuticals Policy and Law

Restricted accessOtherFirst published April, 2002

Adverse Event Reporting and Standardized Medical Terminologies: Strengths and Limitations

Stephen A. Goldman

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 2005

Adverse Event Analysis and MedDRA: Business as Usual or Challenge? *

Jürgen Kübler, Richardus Vonk, Stefan Beimel [...]

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 2000

Establishing a Meddra Safety Surveillance Unit

Thanh T. van Doan

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2002

Converting Legacy Data to Meddra: Approach and Implications *

Thanh Van T. Doan

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2006

Proposed Terminology Changes to Facilitate the Analysis of MedDRA®-Coded Data

Anna C. Zhao-Wong, Eva Rump, Tomás Moraleda [...]

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1998

A Preliminary Assessment of the Impact of MEDDRA on Adverse Event Reports and Product Labeling

Claudia A. White

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published July, 2001

Using Meddra for Adverse Events in Cancer Trials: Experience,Caveats,and Advice

Lothar T. Tremmel

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published October, 2001

Defining Treatment-Emergent Adverse Events with the Medical Dictionary for Regulatory Activities (MedDRA) *

Mary E. Nilsson, Stephanie C. Koke

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published October, 2002

Data Normalization Techniques and Autocoding Algorithms for the Medical Dictionary for Regulatory Activities (MedDRA)

Mike Don Tucker

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published August, 2001

Medicinal Dictionary (MedDRA): Indications and reactions. Applications in pharmacovigilance

Arthur P. Meiners

Pharmaceuticals Policy and Law

Restricted accessOtherFirst published April, 2002

Adverse Event Reporting and Standardized Medical Terminologies: Strengths and Limitations

Stephen A. Goldman

Therapeutic Innovation & Regulatory Science